Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.
Ryan Livingston
Advertisement
Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.
Articles by Ryan Livingston
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
4
Key Federal Legislation Impacting Managed Care Pharmacy: Geni Tunstall, JD
5
